Arrowhead stock gains on trial data for Alzheimer’s drug (ARWR)
· seekingalpha.com
Arrowhead Pharmaceuticals (ARWR) stock jumps as the company posts data from its ongoing Phase 1/2a study of its Alzheimer's therapy, ARO-MAPT. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...